AMBI Skin Cream Recalled Due to Improper Storage Conditions
AMBI Skin Cream for normal and oily skin was recalled due to storage temperature deviations. Products were distributed to Family Dollar Stores between April and June 2022.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall, but no illnesses or injuries have been reported. The hazard is improper storage conditions, which presents a theoretical risk rather than confirmed harm. Per the severity rubric, when no illnesses are reported and the hazard is theoretical, the maximum score is 3 (High).
Plain-English summary
AMBI Skin Cream is being recalled. Two products are affected: AMBI Skin Cream for normal skin (2 OZ, SKU 2024219) and AMBI Skin Cream for oily skin (2 OZ, SKU 2024222).
The recall is due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the products were held outside appropriate storage temperature conditions. The affected products were distributed to specific Family Dollar Stores between April 30, 2022 and June 10, 2022.
No illnesses or injuries have been reported. Consumers who purchased these products should discontinue use. Those with questions about whether their product is affected should check the SKU number on their package or contact their retailer.
The recalled product
- Product
- AMBI Skin Cream for normal skin 2 OZ SKU 2024219 AMBI Skin Cream for oily skin 2 OZ SKU 2024222. distributed to specific Family Dollar Stores 04/30/2022 through 06/10/2022.
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Topical skincare
- Hazard
- improper-storage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- SKUs: 2024219
- 2024222
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27